Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases

Podobne zapisy

• Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
  od: Mallick, Rajiv, i wsp.
  Wydane: (2018)
• Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
  od: Hagan, John B., i wsp.
  Wydane: (2010)
• Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
  od: van Schaik, Ivo N., i wsp.
  Wydane: (2019)
• Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells
  od: Saito, Masako, i wsp.
  Wydane: (2011)
• Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
  od: Jolles, Stephen, i wsp.
  Wydane: (2018)